Telomir Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
John Paul DeJoria, through his family trust, has disclosed a 9.438% beneficial ownership stake in Telomir Pharmaceuticals, Inc.
NASDAQ
John Paul DeJoria, through his family trust and individually, has reported a 5.5% beneficial ownership stake in Telomir Pharmaceuticals, Inc.